Skip to main content
. 2019 Jul 22;33(8):e22975. doi: 10.1002/jcla.22975

Figure 2.

Figure 2

PFS and OS in HCC patients. HCC patients treated by DEB‐TACE with CSM showed mean PFS of 13.7 mo (95% CI: 11.7‐15.8 mo) (A) and mean OS of 18.8 mo (95% CI: 16.3‐21.2 mo) (B). Survival analysis was performed using Kaplan‐Meier method and determined by the Log‐rank test. PFS, progression‐free survival; OS, overall survival; HCC, hepatocellular carcinoma; DEB‐TACE, drug‐eluting beads‐transarterial chemoembolization; CSM, CalliSpheres® Microspheres